Lipid nanoparticles with erythrocyte cell-membrane proteins

Bóta, Attila; Fehér, Bence; Wacha, András; Juhász, Tünde; Szabó, Dániel; Turiák, Lilla; Gaál, Anikó; Varga, Zoltán; Amenitsch, Heinz; Mihály, Judith

doi:10.1016/j.molliq.2022.120791

Cited by 3 publications

(1 citation statement)

References 42 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NEs are popular drug-delivery vehicles because of their increased in vivo circulation half-life and colloidal stability 172 , and they can extravasate into tumour tissue to release their cargo on the spot - in contrast to larger GUVs that would remain contained within the circulatory system 173 . Compared to GUVs, their production is relatively simple, but many of the RBC’s transmembrane proteins are lost during preparation 174 . Therapeutic formulations of NEs have already been applied in vivo with remarkably improved therapeutic results 171 , 175 , 176 .…”

Section: Alternative Rbc Biomimetic Systemsmentioning

confidence: 99%

Artificial cells for in vivo biomedical applications through red blood cell biomimicry

Waeterschoot,

Gosselé,

Lemež

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Recent research in artificial cell production holds promise for the development of delivery agents with therapeutic effects akin to real cells. To succeed in these applications, these systems need to survive the circulatory conditions. In this review we present strategies that, inspired by the endurance of red blood cells, have enhanced the viability of large, cell-like vehicles for in vivo therapeutic use, particularly focusing on giant unilamellar vesicles. Insights from red blood cells can guide modifications that could transform these platforms into advanced drug delivery vehicles, showcasing biomimicry’s potential in shaping the future of therapeutic applications.

show abstract

Section: Alternative Rbc Biomimetic Systemsmentioning

confidence: 99%

Artificial cells for in vivo biomedical applications through red blood cell biomimicry

Waeterschoot,

Gosselé,

Lemež

et al. 2024

Nat Commun

View full text Add to dashboard Cite

show abstract

Biomimetic Cell Membrane‐Coated Nanoparticles for Cancer Theranostics

Jiang,

Zhan,

Ding

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

Nanoparticles can enhance drugs accumulating at the tumor site and hold tremendous promise for achieving effective tumor treatment. However, due to the complexity of cancer heterogeneity and suppressive tumor microenvironment, the delivery of traditional nanoparticles has poor infiltration and off‐target effects, making it difficult to control the drug release rate and causing off‐target toxicity. In recent years, cell membrane‐coated biomimetic nanoparticles have been developed, which have both the natural characteristics of biomembranes and the physical characteristics of traditional nanoparticles, thus improving the homologous targeting ability of nanoparticles to tumor cells and better biocompatibility. In this paper, we reviewed the application of single cell membrane and hybrid cell membrane‐coated biomimetic nanoparticles in the integration for tumor diagnosis and treatment. We talked about the preparation methods of cell membrane‐coated nanoparticles, the targeting mechanisms, and the effects of imaging and therapeutic outcomes of different cell membrane‐coated biomimetic nanoparticles in detail. Finally, we discussed the existing problems and prospects of cell membrane‐coated biomimetic nanomaterials.

show abstract